Detailed company information
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Last Updated: Sep 2026
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q1Released: May 13, 2023
Earnings Transcript for 2022 - Q4Released: Mar 08, 2023
Earnings Transcript for 2022 - Q3Released: Nov 14, 2022
Earnings Transcript for 2022 - Q2Released: Aug 15, 2022
Earnings Transcript for 2022 - Q1Released: May 12, 2022
Earnings Transcript for 2021 - Q4Released: Mar 10, 2022
Earnings Transcript for 2020 - Q4Released: Mar 25, 2021
Earnings Transcript for 2020 - Q2Released: Aug 05, 2020
Earnings Transcript for 2020 - Q1Released: May 10, 2020
Earnings Transcript for 2019 - Q4Released: Mar 11, 2020
Earnings Transcript for 2019 - Q3Released: Nov 08, 2019
Earnings Transcript for 2019 - Q2Released: Aug 08, 2019
Earnings Transcript for 2019 - Q1Released: May 10, 2019
KURA Kura Oncology, Inc.
Dafinchi
